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Abstract
Background:  Genetic factors that predict responses to diet may ultimately be used to
individualize dietary recommendations. We used physiogenomics to explore associations among
polymorphisms in candidate genes and changes in relative body fat (Δ%BF) to low fat and low
carbohydrate diets.
Methods: We assessed Δ%BF using dual energy X-ray absorptiometry (DXA) in 93 healthy adults
who consumed a low carbohydrate diet (carbohydrate ~12% total energy) (LC diet) and in 70, a
low fat diet (fat ~25% total energy) (LF diet). Fifty-three single nucleotide polymorphisms (SNPs)
selected from 28 candidate genes involved in food intake, energy homeostasis, and adipocyte
regulation were ranked according to probability of association with the change in %BF using
multiple linear regression.
Results: Dieting reduced %BF by 3.0 ± 2.6% (absolute units) for LC and 1.9 ± 1.6% for LF (p <
0.01). SNPs in nine genes were significantly associated with Δ%BF, with four significant after
correction for multiple statistical testing: rs322695 near the retinoic acid receptor beta (RARB) (p
< 0.005), rs2838549 in the hepatic phosphofructokinase (PFKL), and rs3100722 in the histamine N-
methyl transferase (HNMT) genes (both p < 0.041) due to LF; and the rs5950584 SNP in the
angiotensin receptor Type II (AGTR2) gene due to LC (p < 0.021).
Conclusion: Fat loss under LC and LF diet regimes appears to have distinct mechanisms, with PFKL
and HNMT and RARB involved in fat restriction; and AGTR2 involved in carbohydrate restriction.
These discoveries could provide clues to important physiologic mechanisms underlying the Δ%BF
to low carbohydrate and low fat diets.
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Introduction
Dietary modification remains a logical and fundamental
approach to the treatment of obesity. Achieving success
may depend on the diet chosen [1-4] and on innate and
genetically inherited metabolic characteristics [5]. Ideally,
a weight loss diet regimen should decrease excess adipose
tissue mass, including the more important visceral fat,
and preserve lean tissue. While weight loss occurs with
any dietary strategy that restricts energy intake, it is clear
that macronutrient composition has a role in determining
adipose tissue and lean body mass responses [6]. In par-
ticular, changes in dietary carbohydrate affect substrate
metabolism through responses of hormones such as insu-
lin [7] that clearly induce macronutrient-dependent
expression of genes [8,9]. Further, there are interindivid-
ual differences in metabolic processing of both carbohy-
drate [10] and fat [11,12] that have been implicated in
obesity. In the present study, we compared the genetic var-
iability associated with relative fat loss induced by energy
restricted diets that varied in carbohydrate content. Such
knowledge may ultimately lead to the development of
DNA guided dietary recommendations.
The genes that influence the adipose tissue and lean body
(skeletal muscle + bone) mass compartments alone or in
response to dietary intervention remain uncharacterized
[13,14]. Sorenson et al. [15] examined 42 SNPs in 26 can-
didate genes hypothesized to modulate obesity but found
none to be predictive of the change in body mass index
(BMI) induced by dietary restriction of either carbohy-
drate or fat. Although commonly used, BMI is not a pre-
cise surrogate index of adiposity. Its use as a phenotype
may make genetic associations with a change in adiposity,
difficult to discern.
In order to simultaneously assess relationships between
many gene variants and the phenotype of relative body
fat, the present study employed physiogenomics [16], a
medical application of sensitivity analysis and systems
engineering. Sensitivity analysis is the study of the rela-
tionship between input and output from a system as
determined by system components. Physiogenomics uti-
lizes the genes as the components of the system. The gene
variability, measured by single nucleotide polymor-
phisms (SNPs), is correlated to physiological responses,
the output, of a diversely responsive human population.
Physiogenomics determines how the SNP frequency var-
ies among individuals similarly responding to the input
over the entire range of the response distribution. We have
previously utilized physiogenomics to identify genes rele-
vant to dietary weight reduction [5] and drug-induced
side effects [17-19].
The present study succeeds a previous physiogenomic
study which found that the total body weight loss
response to carbohydrate restriction was associated with
variants in gastric lipase (LIPF), hepatic glycogen synthase
(GYS2), cholesteryl ester transfer protein (CETP) and
galanin (GAL) genes [5]. Here we extend that study to
compare carbohydrate restriction to fat restriction, using
the change in relative fat measured by dual energy X ray
absorptiometry (DXA), an accurate method to assess per-
cent fat [20,21], as a phenotype. We hypothesized that
genes representative of food intake, energy homeostasis,
and adipocyte regulation may explain the variability in
the change in percent body fat accomplished through
restriction of fat or carbohydrate.
Methods
Subjects and study design
The subjects included 93 adults who participated in very
low carbohydrate (LC) [1,22-25] and 70 who participated
in low fat (LF) dietary studies [1,22] designed to examine
the effects on weight loss, body composition, and other
metabolic responses related to cardiovascular disease in
the Human Performance Laboratory at the University of
Connecticut (Table 1). The subjects were free of diabetes,
cardiovascular, respiratory, gastrointestinal, thyroid and
other metabolic disease. They were weight stable (± 2 kg)
the month prior to starting the study. Subjects were not
allowed to use nutritional supplements (except a daily
multi-vitamin/mineral), or take medications to control
blood lipids or glucose. The majority of subjects were sed-
entary and all were instructed to maintain the same level
of physical activity throughout the study. The LC diet
intervention was 12 weeks for the majority of subjects, but
in some cases the duration was shorter (4–6 wk). Before
and after LC and LF, body mass was determined in the
morning after an overnight fast on a calibrated digital
scale with subjects in light clothing and not wearing
shoes. All subjects signed an informed consent document
approved by the University of Connecticut Institutional
Review Board.
Dietary protocols
Low carbohydrate (LC)
The LC diet intervention has been described previously
[5]. Subjects were free-living with the main goal to restrict
carbohydrate (CHO) to a level that induced a small level
of ketosis. There were no restrictions on the type of fat
from saturated and unsaturated sources or cholesterol lev-
els. Foods commonly consumed were beef (e.g., ham-
burger, steak), poultry (e.g., chicken, turkey), fish,
vegetable oils, various nuts/seeds and peanut butter, mod-
erate amounts of vegetables, salads with low CHO dress-
ing, moderate amounts of cheese, eggs, protein drinks,
and water or low CHO diet drinks. To ensure appropriate
CHO restriction, subjects monitored their level of ketosis
daily using urine reagent strips that produce a relative
color change in the presence of one of the primaryNutrition & Metabolism 2008, 5:4 http://www.nutritionandmetabolism.com/content/5/1/4
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ketones, acetoacetic acid. Blood ketones were also
checked during the diets. On this basis, all subjects were
in ketosis for the majority of the experimental period. The
actual mean nutrient breakdown of the diets as a percent-
age of total energy was obtained from at least 15 days of
weighed food records across the various studies from
which subjects were pooled.
Low fat (LF)
The LF diet was designed to provide <10% of total calories
from saturated fat and <300 mg cholesterol/day [1].
Foods encouraged included whole grains (breads, cereals,
and pastas), fruit and fruit juices, vegetables, vegetable
oils, low-fat dairy and lean meat products. Standard dia-
betic exchange lists were used to foster a macronutrient
balance of protein (~20% energy), fat (~25% energy), and
carbohydrate (~55% of energy). All subjects received
extensive initial verbal and written instructions and
weekly follow-up dietetic education. Subjects received
thorough instructions for completing detailed weighed
food records during baseline and various phases of the
diet that were subsequently analyzed using regularly
updated nutrient analysis software (NUTRITIONIST
PRO™, Version 1.5, First Databank Inc, The Hearst Corpo-
ration, San Bruno, CA). The actual mean nutrient break-
down of the diets as a percentage of total energy was
obtained from at least 15 days of weighed food records.
Percent body fat measurement
Whole body composition was assessed using DXA (Prod-
igy™, Lunar Corporation, Madison, WI). Analyses were
performed by the same technician (blinded as to dietary
intervention) using commercial software (enCORE ver-
sion 6.00.270). Percent body fat was calculated as soft tis-
sue fat mass divided by the sum of soft tissue fat mass, soft
tissue lean body mass, and bone mineral content. Coeffi-
cients of variation for lean body mass, fat mass, and bone
mineral content on repeat scans with repositioning on a
group of men and women in our laboratory were 0.4, 1.4,
and 0.6%, respectively.
Selection of candidate genes
To identify genes involved in physiological responses to
carbohydrate versus fat ingestion, we canvassed physio-
logical pathways and biological processes relevant to the
regulation of adiposity, including but not limited to eat-
ing behavior, digestion and absorption, hormonal signal-
ing in the prandial and postprandial period, the
regulation of fuel distribution and processing, and the
control of adipocyte size and proliferation. From these
categories, we selected 28 genes to represent three catego-
ries: food intake, energy homeostasis, and adipocyte regu-
lation. Table 2 provides summary information relevant to
the genes and SNPs. The role for each gene is described
below.
Food intake
The GAL and GHRL genes, expressed in the hypothalamus
[26] and stomach [27], respectively, encode for the orexi-
gens galanin and ghrelin, respectively [26,27]. HNMT
encodes for histamine N-methyl transferase, which inacti-
vates histamine and is widely expressed in the stomach,
thymus, lung, spleen, kidney, and particularly the brain
[28]. LIPF  encodes for gastric lipase, which hydrolyzes
triglycerides, freeing fatty acids for intestinal uptake [29].
The PYY gene encodes for peptide YY, a gut endocrine fac-
tor that circulates after meals [30]. NPY encodes for neu-
ropeptide Y, an abundant brain and autonomic
neurotransmitter [31] and potent orexigen [32]. NPY5R
encodes for one of five neuropeptide Y receptors studied
in relation to energy balance [33]. The LEPR gene encodes
for the leptin receptor, believed critical in the central reg-
Table 1: Demographic characteristics of the subjects in the low fat (LF) and low carbohydrate (LC) diet groups.
Low Fat Low Carbohydrate
Variable Value Subjects Baseline % 
Body fat
Mean change, % Body 
Fat [absolute %]
Subjects Baseline % 
Body fat
Mean change, % Body 
Fat [absolute %]
All All 70 35.5 -2.02 93 34.6 -2.97
Gender Female 33 37.6 -1.49 31 38.0 -1.27
Male 37 33.7 -2.43 62 32.9 -3.80
Age <20 8 34.4 -3.00 7 34.8 -4.70
20–30 26 32.2 -1.56 36 33.4 -2.36
30–40 17 39.6 -2.32 20 37.2 -2.81
40–50 13 33.9 -2.60 21 35.0 -2.72
50–60 7 41.6 -0.85 6 32.6 -4.93
60–70 0 - - 3 32.5 -6.00
Heritage African Amer 4 37.9 -1.63 5 36.7 -2.82
Asian 1 36.5 -3.08 4 36.2 -3.34
Caucasian 63 35.4 -2.01 81 34.5 -2.50
Hispanic 2 32.3 -0.99 3 34.7 -2.16Nutrition & Metabolism 2008, 5:4 http://www.nutritionandmetabolism.com/content/5/1/4
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ulation of energy homeostasis [34]. MC3R encodes for the
melanocortin receptor 3, which regulates energy homeos-
tasis in response to neuropeptides secreted by pro-opi-
omelanocortin and agouti related peptide releasing
neurons [35]. APOA4 encodes for apolipoprotein A-IV, is
expressed by intestinal cells in response to fat absorption
[36], and has a hypothesized, centrally-mediated role in
the regulation of energy intake [36].
Table 2: Genes and SNPs analyzed for associations with percent body fat change profiles for LF and LC groups.
Area Pathway Gene Symbol SNP Type
Food Intake Neural galanin GAL rs694066 intron 1
leptin receptor LEPR rs7602 intron 1 (3' UTR on another gene)
rs1171276 intron 1 (untranslated)
rs8179183 exon 12, N656K
melanocortin 3 receptor MC3R rs6024725 ~10 kb upstream
neuropeptide Y NPY rs1468271 intron 1
neuropeptide Y receptor Y5 NPY5R rs11100494 intron 3
rs6837793 ~9 kb upstream
Neural/Gut histamine N-methyltransferase HNMT rs1801105 exon 4, I105T
rs12691940 intron 2
Gut apolipoprotein A-IV APOA4 rs675 T367S, exon 3
rs5092 exon 2, T29T
ghrelin precursor GHRL rs26312 ~1 kb upstream
lipase, gastric LIPF rs814628 exon 4, A161T
peptide YY PYY rs1058046 exon 2, R72T
rs231460 ~1.8 kb upstream
Energy Homeostasis Metabolic Enzyme glycogen synthase kinase 3 beta GSK3B rs4688046 intron 3
rs334555 intron 1
rs10934502 intron 2
glycogen synthase 1 (muscle) GYS1 rs2287754 5' UTR
glycogen synthase 2 (liver) GYS2 rs1478290 upstream, ~3.5 Kb
rs2306179 intron 5
rs10505873 intron 3
phosphofructokinase, liver PFKL rs2838549 intron 8
phosphofructokinase, muscle PFKM rs2269935 ~700 bp upstream
pyruvate kinase, liver and RBC PKLR rs3762272 intron 2
pyruvate kinase, muscle PKM2 rs2856929 intron 7 (MT)
Nuclear Signaling retinoic acid receptor, alpha RARA rs4890109 intron 3
rs9904270 ~7.5 kb upstream
retinoic acid receptor, beta RARB rs2033447 intron 2 (MT)
rs1290443 intron 3 (MT)
rs322695 ~100 kb upstream
retinoic acid receptor, gamma RARG rs10082776 intron 2 (untranslated)
retinoid X receptor, alpha RXRA rs4917348 ~100 kbp upstream
rs3750546 ~100 kb upstream
rs3118536 intron 3
retinoid X receptor, gamma RXRG rs157864 intron 4
Adipocyte Regulation Adipokine-related adiponectin receptor 2 ADIPOR2 rs2058112 intron 1 (untranslated?)
rs7975375 intron 1 (untranslated?)
angiotensin II receptor, type 1 AGTR1 rs12695902 intron 3
rs931490 intron 2 (untranslated?), (MT)
angiotensin II receptor, type 2 AGTR2 rs5950584 ~4.5 kb upstream
resistin RETN rs3219177 intron 1
Lipid Metabolic apolipoprotein E APOE rs7412 exon 3, C176R, *2–>*3
rs429358 exon 3, R130C, *4–>*3
rs405509 ~200 bp upstream
rs439401 ~1.5 kbp downstream
rs446037 ~1.5 kbp upstream
cholesteryl ester transfer protein, plasma CETP rs5883 exon 9, F287F
rs1532624 intron 7
rs3764261 ~2.6 kb upstream
rs5880 nonsynonymous, P390ANutrition & Metabolism 2008, 5:4 http://www.nutritionandmetabolism.com/content/5/1/4
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Energy homeostasis
GSK3B encodes for glycogen synthase kinase 3 β-9, which
inactivates glycogen synthase by phosphorylation [37].
Glycogen synthase (GYS) catalyzes the rate-limiting step
in glycogen synthesis. GYS1 and GYS2 are expressed liver
and muscle, respectively. The PFKL  and  PFKM  genes
encode the liver [38] and muscle [39] isoforms of phos-
phofructokinase, respectively. Phosphofructokinase is the
key regulatory enzyme for glycolysis. PKLR  and  PKM2
encode for liver and muscle isoforms of pyruvate kinase,
an enzyme of glycolysis and gluconeogenesis [37]. The
RARA, RARB, and RARG; and RXRA and RXRG genes are
members of the nuclear receptor superfamily. The RAR
and RXR gene products participate in the regulation of
energy balance at a neural level [40] and their expression
in hepatic and adipose tissues is diet-responsive [41,42].
Adipose regulation
The  ACGT1  and  AGTR2  genes express angiotensin II
receptors type I and II. Both play roles in adipocyte regu-
lation and cellularity [43]. The ADIPOR2 gene encodes
adiponectin receptor type I; muscle expression of this
gene plays a role in non-oxidative glycolysis [44]. Apoli-
poprotein E and cholesteryl ester protein, encoded by the
APOE  and  CETP  genes, respectively, have widespread
roles in lipid metabolism. Both are expressed in adi-
pocytes [45-47] and subject to nutritional regulation
[45,48]. RSTN encodes for the adipocyte-secreted factor,
resistin, which is increased in obesity [49].
Laboratory analysis
Blood samples were collected from an arm vein into tubes
for DNA extraction. The DNA was extracted from 8.5 mL
of whole blood using the PreAnalytiX PAXgene DNA iso-
lation kit (Qiagen Inc, Valencia, CA). For some earlier par-
ticipants, neither whole blood nor DNA were available, so
DNA from lymphocytes remaining in archived serum
samples were amplified using the QiaGen REPLI-g Whole
Genome Amplification kit. Genotyping was performed
using the Illumina BeadArray™ platform and the Golden-
Gate™ assay [50,51]. The assay information and observed
allele frequencies for the SNPs used in this study are listed
in Table 3.
Data analysis
All statistical analysis was performed using the R Statistics
Language and Environment [52-54]. Covariates were ana-
lyzed using multiple linear regression, and selected using
the stepwise procedure. The change in relative fat mass,
Δ%BF, was calculated as the difference between post-diet
and baseline measurements of %BF. To test for associa-
tion with SNP genotypes, the residual of Δ%BF after cov-
ariate analysis was tested using linear regression on the
SNP genotypes. SNP genotype was coded quantitatively as
a numerical variable indicating the number of minor alle-
les: 0 for major homozygotes, 1 for heterozygotes, and 2
for minor homozygotes. The F-statistic p-value for the
SNP variable was used to evaluate the significance of asso-
ciation. To test the validity of the p-values, we also per-
formed an independent calculation of the p-values using
permutation testing. The ranking of the first three SNPs
were identical under permutation and F-statistic analyses
(data not shown). To account for the multiple testing of
53 SNPs, we calculated adjusted p-values using Benjamini
and Hochberg's false discovery rate (FDR) procedure [55-
57].
LOESS representation
We use a locally smoothed function of the SNP frequency
as it varies with Δ%BF to visually represent the nature of
an association. LOESS (LOcally wEighted Scatter plot
Smooth) is a method to smooth data using a locally
weighted linear regression [58,59]. At each point in the
LOESS curve, a quadratic polynomial is fitted to the data
in the vicinity of that point. The data are weighted such
that they contribute less if they are further away, according
to the tricubic function
where x is the abscissa of the point to be estimated, the xi
are the data points in the vicinity, and d(x) is the maxi-
mum distance of x to the xi.
Results
Dietary intake
The intake of total dietary energy at baseline did not differ
between groups, nor did absolute amounts of protein, car-
bohydrate, and fat (Table 4). Relative to total energy
intake, the intakes of protein, carbohydrate, and fat energy
at baseline for LC and LF, expressed as percent of total
energy, were 15.9%, 50.2%, and 32.6; and 16.6%, 47.7%,
and 34.9%; respectively.
Dietary intervention decreased mean total energy intake
to 1470 kcal in LF and to 1705 kcal/day in LC (p < 0.01),
representing mean changes from baseline of -32.5% and -
26.5%, respectively. During intervention, carbohydrate
intake averaged 212 g/day (57% of total energy) in LF
compared to 53 g/day (12% of total energy intake) in LC.
Protein intake averaged 94 g/day (19% of total energy) in
LF and 115 g/day (28% of total energy) in LC. Fat intake
averaged 37 g/day (23% of total energy) in LF and 112 g/
day (59% of total energy) in LC. All between-group differ-
ences in macronutrient gram intake were significant (p <
1e-10, Table 4).
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Table 3: Assay DNA sequences for the SNPs analyzed.
SNP Gene Chr mac min maj Freq Sequence Context
rs694066 GAL 11 20 A G 0.09 TTCTAAGTCCTCTGCCATGCC [A/G]GGAAAGCCTGGGTGCACCCA
rs7602 LEPR 1 29 A G 0.16 CTTGGAGAGGCAGATAACGCT [A/G]AAGCAGGCCTCTCATGACCC
rs1171276 APOA4 1 23 A G 0.13 AGTTTCATGTACATTAAATAT [A/G]AATTTCTTTTGGCTGGAAAT
rs8179183 APOA4 1 31 C G 0.18 TAATGGAGATACTATGAAAAA [C/G]GAGAAAAATGTCACTTTACT
rs6024725 MC3R 20 31 T C 0.22 CCTAGAGACATATCTCAGTTA [A/G]GTTTTAGCCTCACCAGTATT
rs1468271 NPY 7 12 A G 0.06 GACCCTGTAATTTTCAGAAAC [A/G]CACATAGGAGTGGGTGTCTG
rs11100494 NPY5R 4 10 A C 0.05 CAGAAAGATGTCATCATCCAG [A/C]ATTGCGTCCACACAGTCAAC
rs6837793 NPY5R 4 18 A G 0.10 ATGAATTGTCACTCAGAAGAA [A/G]CTTAATAGGCATTAATACTA
rs1801105 HNMT 2 14 T C 0.08 TTTACGTTCTCGAGGTTCGAT [A/G]TCTTGGCTACAAGCTCTAAA
rs12691940 HNMT 2 66 A G 0.00 AATCAACCAAGTGGAAGAAAG [A/G]ATATCAGAGTCTGAAGACAA
rs675 APOA4 11 32 T A 0.16 GAGAAAGAGAGCCAGGACAAG [A/T]CTCTCTCCCTCCCTGAGCTG
rs5092 APOA4 11 30 A G 0.16 CAGTGCTGACCAGGTGGCCAC [A/G]GTGATGTGGGACTACTTCAG
rs26312 GHRL 3 36 A G 0.15 GCTGTTGCTGCTCTGGCCTCT [A/G]TGAGCCCCGGGAGTCCGCAG
rs814628 LIPF 10 26 A G 0.14 ATCGACTTCATTGTAAAGAAA [A/G]CTGGACAGAAGCAGCTACAC
rs1058046 PYY 17 78 C G 0.38 GGAAAAGAGACGGCCCGGACA [C/G]GCTTCTTTCCAAAACGTTCT
rs231460 PYY 17 43 T C 0.23 TGCTCACCCTAGGATGGAGGG [A/G]GCAGTGGGGGCTGGTTAGGA
rs4688046 GSK3B 3 44 T C 0.24 TAGTAAACTATTTCTTCCCAT [A/G]GGAGAAGATGGATTCTTTTC
rs334555 GSK3B 3 24 C G 0.13 AATTATATCTTATTATTAAAA [C/G]TCTACCAACTCAAAGCTTCC
rs10934502 GSK3B 3 40 T C 0.24 GCTTCCTTATGTAAAATGTAG [A/G]TATTTCTAAAGTAACGCAAT
rs2287754 GYS1 19 25 A G 0.15 CGGGAAGCTTGCAAGACGCTC [A/G]GCTTCCTATTGCAAGACCGC
rs1478290 GYS2 12 59 T G 0.26 AATGTGGCTGAAGCCAAAAGC [A/C]TAATGAATGAGGGGAAGCCT
rs2306179 GYS2 12 52 A G 0.27 TTTCAGTAGGTTTGCAGGGAA [A/G]CCAACTCAAAGCTATATCTG
rs10505873 GYS2 12 67 T C 0.49 TGCTCAGCCTTCTTCAATGAC [A/G]GTGTTTTGCTATTGTCTCTA
rs2838549 PFKL 21 15 A G 0.09 GGACACTGGTTCCACCTCCGC [A/G]TGGCTGTACAGTGCTGCCGA
rs2269935 PFKM 12 53 A C 0.26 CGGCAATTAGACTGGCTAGAG [A/C]CACCTCAGTCAGGCTCTCCC
rs3762272 PKLR 1 13 A G 0.06 AACAAAGATTCTCCTTTCCTC [A/G]TTCACCACTTTCTTGCTGTT
rs2856929 PKM2 15 39 A G 0.24 CAGGCTCAGGGTCTAAATTCC [A/G]TATCCTTTCTTCCATACCCT
rs4890109 RARA 17 10 T G 0.05 GGCTGCTCAGGGCCTCGTCCA [A/C]CCCCAGCCTGACAGAGAGCT
rs9904270 RARA 17 29 T C 0.15 GCCTTCCCCTTAGAGAAGAGC [A/G]CCTGCCAGACAAGGGAGAAG
rs2033447 RARB 3 43 T C 0.20 ATGCCGGGTGCTAGAGATACA [A/G]CAGTGAACATGACAAAGTTC
rs1290443 RARB 3 30 A G 0.15 AGAAGCTCTTTCATGTTGTCA [A/G]TTTTAGAAATCCAAATCATT
rs322695 RARB 3 29 A G 0.15 CCTGTAGGATTGTGTTCCTCT [A/G]AAACTGTCCCCTAAATTATG
rs2838549 PFKL 21 51 A G 0.09 GGACACTGGTTCCACCTCCGC [A/G]TGGCTGTACAGTGCTGCCGA
rs157864 RXRG 1 17 T C 0.10 ATGATATTGAATTAAAGGAAA [A/G]TGAATGGTCTCAGTCAGAGA
rs3118536 RXRA 9 31 A C 0.14 CTGCAGGTGCACGGTTTCCTG [A/C]TTGCCCAGGTGTCTCTGAGC
rs4917348 RXRA 9 40 A G 0.21 GGTGGGGTTAGAGGGGATGGT [A/G]CCTGGCAGTGTGCAGCAGAC
rs3750546 RXRA 9 43 A G 0.20 CCTGAGGATGAAGGGGCGTCC [A/G]TGGCCAGGCAGCAGTGAGAA
rs157864 PYY 1 17 T C 0.10 ATGATATTGAATTAAAGGAAA [A/G]TGAATGGTCTCAGTCAGAGA
rs2058112 ADIPOR2 12 27 T C 0.15 TCTTCTTGCCCTACATACTTC [A/G]AAAGCCCTTGGAGAAATCCT
rs7975375 ADIPOR2 12 31 T C 0.17 CTTTTCACAGGAAAATTTCTT [A/G]GGAGTCTATTGTCACTGTCT
rs12695902 AGTR1 3 16 A G 0.09 CATCAGGATTATCAGCATTTA [A/G]GCCAGAGTTGCAAATTAAGT
rs931490 AGTR1 3 23 A G 0.19 GGCGCCCCCTGGACTTCTGCT [A/G]GAATTTAGATTTAAATAGAT
rs5950584 AGTR2 X 8 T G 0.04 CTATCCTCAAATGCTATATAA [A/C]CCAACTGGTGGAAAAAAATT
rs3219177 RETN 19 31 T C 0.15 CCAGGGATCAGTGAGGTCTCT [A/G]AGACCCTTGGGGAGCTTGCC
rs7412 APOE 19 18 T C 0.08 CGGCCTGGTACACTGCCAGGC [A/G]CTTCTGCAGGTCATCGGCAT
rs429358 APOE 19 31 T C 0.14 GGTACTGCACCAGGCGGCCGC [A/G]CACGTCCTCCATGTCCGCGC
rs405509 APOE 19 79 A C 0.00 GAGGACACCTCGCCCAGTAAT [A/C]CAGACACCCTCCTCCATTCT
rs439401 APOE 19 59 T C 0.34 GAGAACTGAGGGGGTGGGAGG [A/G]GAAGAGAGTGCCGGCGGCTC
rs446037 APOE 19 5 A C 0.02 AGACACAGGTGACCCAACTCC [A/C]ATGGCTGGCCTAGGCCCCTC
rs5883 CETP 16 13 T C 0.06 AGCTACCTTGGCCAGCGAGTG [A/G]AAGACTCGCTCAGAGAACCA
rs1532624 CETP 16 76 T G 0.00 TCTGCCCCTTTGGGCTGCAGC [A/C]TCACAAGCTGTGTGGCGTTG
rs3764261 CETP 16 46 T G 0.27 AGTGAATGAGATAGCAGACAA [A/C]CCAGATGCCTACCGACAGGT
rs5880 CETP 16 15 C G 0.08 GATATCGTGACTACCGTCCAG [C/G]CCTCCTATTCTAAGAAAAGC
Chr: chromosome location of the gene; mac: the number of minor alleles found; maj: sequence of the most common allele, major; min: sequence of 
the least common allele, minor; Freq: frequency (0.00–1.00) of the minor allele in the study population.Nutrition & Metabolism 2008, 5:4 http://www.nutritionandmetabolism.com/content/5/1/4
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Body mass and composition
There were no differences in body size or composition
between groups at baseline. With diet intervention, the
change in total body, fat, and lean masses were signifi-
cantly greater in LC (Table 5).
Figure 1 depicts the baseline and changes in % body fat
profiles in the LF and LC study populations. The distribu-
tions are approximately normal and the baseline percent
body fat levels for LF (35.4 ± 7.8%) and LC (34.5% ±
7.3%) were not different between groups. Overall LC
induced an absolute decrease in % body fat of 2.98 ±
2.62%, reflecting losses of 4.8 kg of fat mass and 1.42 kg
of lean mass, compared to a % fat decrease of 1.92 ±
1.63% in LF (p < 0.01), reflecting losses of 3.18 kg for fat
mass and 0.70 kg for lean mass. Men outnumbered
women in both study groups and had lower baseline %
body fat in both groups (33.7 vs. 37.6 LF, and 32.9 vs.
38.0 LC) (Table 1). The change in % body fat (Δ%BF) due
to diet was greater for men versus women (Table 5). For
physiogenomics analyses, we employed gender as a cov-
ariate to account for the difference.
Physiogenomic associations
Table 6 lists the results of the association tests, comparing
LF and LC groups. A single SNP rs322695 in the RARB
gene was significantly associated with Δ%BF for both the
LF and LC interventions (p < 0.0001 and p < 0.0121,
respectively). SNPs in the HNMT (rs3100722, p < 0.002)
and PFKL genes (rs2838549, p < 0.002) were significant
only for the LF group. Conversely, the rs5950584 SNP in
the AGTR2 gene was significant only for the LC group (p
< 0.0001). The FDR-corrected p values yield an estimate of
the false positive rate. The following SNPs, RARB
rs322695, HNMT rs1269140, and PFKL rs2838549 and
associations in LF, and the AGTR2 SNP rs5950584 associ-
ation in LC are clearly significant after the FDR correction
(p < 0.005, p < 0.041, p < 0.041, and p < 0.041, respec-
tively). All remaining genes showed no significant associ-
ation in either treatment group, and no gene showed
significance for both diet treatments after adjusting for
multiple tests.
Figure 2 shows the top three markers (according to p
value) related to LF response. The first panel shows the
LOESS curve for SNP rs322695 of the RARB gene. The fre-
quency of the minor allele increases as the Δ%BF response
to the LF diet becomes less pronounced (i.e., no loss of rel-
ative fat mass). The minor allele is completely absent
among subjects with the largest decreases in %BF, and the
frequency is <10% among subjects whose decrease in %BF
exceeded 1%. This finding indicates a strong association
between the RARB marker and response to LF. Similar pat-
terns are seen for HNMT  rs3100722 and PFKL  SNP
rs2838549. The SNPs, RARB SNP rs322695, HNMT SNP
rs3100722, and PFKL  SNP rs2838549, are considered
"torpid" markers for responsiveness to the LF diet.
Figure 3 shows the top three markers associated with
Δ%BF through LC. The first panel in Figure 3 shows the
LOESS curve for SNP rs5950584 of the AGTR2 gene. The
frequency of the minor allele is 30% in the Δ%BF range
Table 4: Dietary data at baseline and during LF and LC interventions.
Intake (grams/day)
Condition Group Total Energy Intake (Kcal/d) Protein Carbohydrate Fat Alcohol
Baseline LF 2176.3 ± 518.4 87.3 ± 23.0 273.2 ± 65.5 80.9 ± 29.7 3.5 ± 6.9
LC 2291.8 ± 735.9 94.3 ± 32.2 267.3 ± 80.5 92.1 ± 43.6 4.4 ± 1.1
Diet LF 1470.0 ± 348.7‡ 69.2 ± 19.0‡ 212.1 ± 59.2 ‡ 37.3 ± 12.6 ‡ 3.1 ± 4.6
LC 1705.2 ± 57.1 ‡† 114.9 ± 32.8 ‡§ 53.2 ± 42.6 ‡§ 111.9 ± 38.7 ‡§ 1.9 ± 3.3 *
† p < 0.01, LC vs. LF, within condition
§ p < 1e-10, LC vs. LF, within condition
* p < 0.05, Baseline vs. Diet, within group
‡ p < 0.0001, Baseline vs. Diet, within group
Table 5: Baseline and change in total body mass and composition for LC and LF.
Baseline Change
Group Total Body Mass Fat Mass Lean Mass Total Body Mass Fat Mass Lean Mass
LF 89.5 ± 21.2 32.2 ± 11.2 54.4 ± 13.1 -4.0 ± 2.9 -3.2 ± 2.2 -0.7 ± 1.9
LC 91.0 ± 20.0 31.8 ± 10.3 56.3 ± 12.8 -6.5 ± 4.1‡ -4.8 ± 3.0‡ -1.4 ± 2.6*
* p < 0.05, LC vs. LF
‡ p < 0.0001, LC vs. LFNutrition & Metabolism 2008, 5:4 http://www.nutritionandmetabolism.com/content/5/1/4
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that is less than -5%, and the minor allele is completely
absent among subjects with subtle change in Δ%BF (i.e.,
no loss of relative fat). A similar pattern is seen with the
GYS2  SNP rs1478290. These two SNPs are considered
reactive markers. The third panel shows the RARB SNP
rs322695 response. The minor allele shows a higher fre-
quency in the subject with little response in Δ%BF, indi-
Distribution of baseline and change in percent body fat for LF (top) and LC (bottom) groups Figure 1
Distribution of baseline and change in percent body fat for LF (top) and LC (bottom) groups. The vertical axes (Frequency) indi-
cates the number of patients observed within a given 10% interval up to 60% (baseline, left panels) or within a given 2% or 5% 
interval (change, right panels) on the horizontal axes. Genotyping was not completed in 3 LF subjects and 7 LC subjects.
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Table 6: Significance levels of gene SNPs associated with % body fat change profiles for carbohydrate-restricted (LC) and fat-restricted 
(LF) diet treatments.
Marker P-value Coefficient FDR
Area SNP Gene LF LC LF LC LF LC
Food Intake rs1801105 HNMT 0.941 0.028 -0.03 -2.03 0.960 0.368
rs12691940 HNMT 0.002 0.755 0.89 -0.12 0.041 0.974
rs1468271 NPY 0.049 0.181 -0.89 -0.90 0.321 0.974
Energy Homeostasis rs1478290 GYS2 0.038 0.009 -0.60 -0.86 0.321 0.209
rs2838549 PFKL 0.002 0.902 1.37 -0.10 0.041 0.974
rs3762272 PKLR 0.048 0.282 -2.24 -0.60 0.321 0.974
rs322695 RARB 0.0001 0.012 1.29 1.03 0.005 0.209
Adipocyte Regulation rs2058112 ADIPOR2 0.044 0.141 -0.89 -0.78 0.321 0.974
rs5950584 AGTR2 0.507 0.0001 -0.77 -3.31 0.732 0.021
rs439401 APOE 0.036 0.691 -0.74 -0.15 0.321 0.974
Abbreviations: Coefficient: linear regression coefficient; FDR: false discovery rate p value, with those in bold type significant at α ≤ 0.05.Nutrition & Metabolism 2008, 5:4 http://www.nutritionandmetabolism.com/content/5/1/4
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cating that the RARB SNP rs322695 is a torpid marker of
responsiveness to LC diet also.
Discussion
The present study shows that genetic associations with
changes in Δ%BF established for genes in pathways
encompassing food intake, energy homeostasis, and adi-
pocyte regulation occur in part through common path-
ways, and in part through different pathways that may
differentiate low fat (LF) and low carbohydrate (LC)
restriction. For both diets, Δ%BF profiles assessed using
DXA were affected by an intergenic SNP upstream of
RARB (rs322695), suggesting that RARB is involved in a
fat loss pathway common to both diets. In contrast, strong
diet-specific associations were also found for a promoter
region SNP in AGTR2 (rs5950584) through LC and PFKL
through LF, suggesting that there are separate mechanisms
for fat loss under the LF and LC diets.
Physiogenomic representation of the most significant genetic associations found in the low carbohydrate group Figure 3
Physiogenomic representation of the most significant genetic associations found in the low carbohydrate group. See Figure 2 
legend for details regarding individual patient genotypes (circles), the distribution of Δ%BF (thin line), and the LOESS fit of the 
allele frequency (thick line) as a function of Δ%BF.
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Physiogenomic representation of the most significant genetic associations found in the low fat diet group Figure 2
Physiogenomic representation of the most significant genetic associations found in the low fat diet group. Individual patient 
genotypes (circles) of each SNP are overlaid on the distribution of Δ%BF (thin line). Each circle represents a patient, with the 
horizontal axis specifying the Δ%BF, and the vertical axis the carrier status for the minor allele: bottom, non-carriers; middle, 
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three panels. The ordinate scales for the genotypes (circles) and Δ%BF distribution (thin line) are not shown. The abscissa is 
labeled for Δ%BF in each panel. The abscissa scale is the same in all three panels and applies identically to marker frequency, 
genotypes, and Δ%BF distribution.
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Physiogenomic associations common to both LF and LC
We observed a significant relationship between the RARB
SNP rs322695 and change in relative fat to both diets after
accounting for nongenetic factors. The relationship was
significant after correction for multiple testing in media-
tion of the LF Δ%BF profiles (p < 0.005). This observation
is noteworthy in light of the putative role of the retinoic
acid system in insulin resistance [60]. The RARB  SNP
rs322695 is found 100 kb upstream and ~600 kb from the
adjacent THR (thyroid hormone receptor) gene. We have
attributed this SNP to RARB because it is the next gene
downstream, and regulatory elements such as enhancers
have been found several hundred kb from their transcrip-
tion start sites. However, it cannot be excluded that the
SNP effect may be unrelated to RARB protein expression,
and rather involve an as yet uncharacterized protein or
non-coding RNA [61]. We are unaware of other polymor-
phisms in the region or near RARB that are related to body
weight or fat regulation in humans and believe this find-
ing to be novel.
The widespread genomic distribution of retinoic acid
response elements (RARE) suggests participation in many
physiological pathways [62-64]. Recently Morgan et al.
[40] described a neural hypothesis for regulation of
annual cycles of body fattening in animals in which
changes in the expression of RAR in the arcuate nucleus of
the brain were noted. Vitamin A deficiency preferentially
decreases hepatic RARB  expression [65], and regulates
hepatic glucose metabolic enzymes [66]. Given that
hepatic enzyme energy regulation occurs in part through
RARB signaling, the present finding allows the hypothesis
that the rs322695 variant affects such regulation.
Physiogenomic associations specific to LF
In addition to the RARB gene, LF Δ%BF profiles had rela-
tionships through PFKL and one SNP in HNMT not found
with LC. The HNMT SNP rs3100722, found at intron 2,
and the PFKL SNP rs2838549, located in intron 8, showed
significant relationships (p < 0.041) after correction for
multiple tests) second in strength only to the RARB gene.
The  HNMT  inhibitor metoprine suppresses feeding in
mice [67]. The present finding enables us to hypothesize
a role for HNMT in the regulation of food intake. Hepatic
phosphofructokinase, a key regulatory enzyme for glycol-
ysis encoded by PFKL, is responsive to macronutrient
changes [68] and is regulated by Vitamin A [66]. Genetic
loci near PFKL have been associated with bipolar affective
disorder [69], but to our knowledge, no SNPs are known
to modulate diet response.
Physiogenomic associations specific to LC
The strongest association (p < 0.003, after correction for
multiple tests) was found in the LC group with SNP
rs5950584 in the angiotensin II receptor, type 2 (AGTR2).
This SNP is found ~4.5 kb upstream in the promoter
region. The AGTR2 gene has a metabolic role that is in
contrast to the vascular role of the angiotensin II type 1
receptor (AGTR1 gene), which we previously found linked
to statin-associated elevations in serum creatine kinase
[17]. Humans and mice express AGTR2 in muscle and adi-
pose tissue, and evidence supports the existence of a func-
tional renin angiotensin II system within adipose tissue
[70]. Mice lacking the AGTR2 receptor are resistant to the
adipocyte hypertrophy and muscle cell insulin resistance
induced by high fat, hypercaloric feeding [71]. AGTR2-
dependent angiotensin II signaling thus could account for
LC unresponsiveness [71]. AGTR2 polymorphisms were
reported to modulate left ventricular mass, through the
polymorphism known as G1675A (rs1403543) in a Euro-
pean population [72], and the T-A combination derived
from G/T rs5193 and G/A rs5194 SNPs in a Cantonese
population [73].
In the present study, the AGTR2 SNP rs5950584 serves as
a reactive marker for the LC diet response. The AGTR2
gene is X-linked, thus men can have only one of either the
T (major) or the G (minor) allele, while women may have
zero, one, or two copies of either allele. Men lost signifi-
cantly more fat than women, which together with the X-
linked nature of the gene might lead to a false positive
result. However, gender was highly significant in our cov-
ariate model, and the association test was performed
adjusting for it, which excludes such a confounding effect.
Another association was found between LC response and
the SNP rs1478290 in the GYS2 gene. The GYS2 product
is glycogen synthase 2, a key regulator of hepatic glucose
storage that is increased by feeding [74]. The GYS2 SNP
rs1478290 is found in the promoter region. We previously
found a different GYS2 SNP, rs2306179, located in intron
5, to be associated with body weight loss in response to LC
diet [5]. The present study, conducted in a larger number
of subjects, found also that a variant in the GYS2 gene is a
response marker for the change in relative fat induced by
LC.
Differentiation of LF and LC diet responses
The number of significant associations overall suggests a
complex system through which regulation of the %BF
phenotype is accomplished. Our list of genes, which is
comparable to other studies to date [15], is exploratory,
not comprehensive, and is representative of food intake,
energy homeostasis, and adipocyte regulation. Virtually
none of the genes in the present study were examined by
previous diet studies [13,15]. Nevertheless, the present
results showed a larger number of gene associations with
Δ%BF profiles in relation to the LF diet compared to the
LC diet. Based simply on the numbers of genes found to
be significantly associated, we infer that the low fat dietNutrition & Metabolism 2008, 5:4 http://www.nutritionandmetabolism.com/content/5/1/4
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utilizes a greater number of signal inputs into the regula-
tion of relative body fat compared to the low carbohydrate
diet. Even after the most stringent correction for multiple
testing, RARB remained significantly associated with LF
Δ%BF and AGTR2 remained associated with LC Δ%BF.
Our findings run counter to those of a recent study [15]
that reported no significant SNP associations with
changes in BMI following carbohydrate or fat restriction
despite using large cohorts. Methodological differences
between the studies are worth noting. The present study
used DXA to precisely assess Δ%BF as opposed to relying
on BMI. Second, different genes were studied. Here, the
selection of genes was designed to reflect Δ%BF pheno-
type variability. In contrast, the SNPs examined by Soren-
son et al. [15] were those demonstrated in previous
reports to affect obesity and not diet response per se.
Macronutrient compositions of the intervention diets
were quite dichotomous in the present study, especially
for carbohydrate (~12% and 57% of total energy as carbo-
hydrate in the LC and LF arms, respectively, in the present
study;  vs. 42% and 57%, respectively, in the study of
Sorenson et al. [15]). We believe a greater imbalance in
the macronutrient combination increases the strength of
the dietary stimuli, which accentuates differences in the
physiological signal intensities associated with each diet,
increasing the chances for detection of physiogenomic
relationships.
Clinical implication
The prevention and treatment of obesity could be more
efficient if dietary recommendations were carried out
based on knowledge of innate individual characteristics
that are genetically predictable. Moreover, adherence to
dietary advice may increase when the advice is personal-
ized. DNA-guided regimens allow healthcare providers to
tailor therapies based on individual patient characteris-
tics, rather than the average diet responses applied in lon-
gitudinal studies [3,75]. A dietary treatment with a higher
average chance for success, for example, may be desirable
for those patients who inherited an ensemble of DNA
markers with the most responsive factors and the least tor-
pid factors for it. We interpret the coefficients associated
with each significant gene marker in Table 4 as either hav-
ing responsive or torpid effects to facilitate fat loss. The
ability to match a diet regimen's genetic "contour" with
the DNA profile of an individual patient marks the begin-
ning of high-resolution personalized nutritional medicine
for the treatment and prevention of obesity.
Limitations
The number of subjects studied, the list of genes analyzed,
and in some cases the frequency of the minor allele in
SNPs of interest, were relatively small. Thus the results will
need to be validated before clinical application. Neverthe-
less, the RARB and AGTR2 results are clearly significant
even when fully and most conservatively corrected for
multiple comparisons. The p-values were confirmed by
non-parametric permutation analysis, excluding non-nor-
mal distribution as a source of false positives. In addition,
the RARB result was found in the LF group and independ-
ently confirmed in the LC group. Although we assessed
only a small sample of SNPs in the genome, this study
included 53 SNPs from 28 genes representing a larger
ensemble of genetic probes than other published diet
studies. The data for the present study were compiled
from a series of studies in whom the majority of subjects
were of European ancestry. We lack power to detect ethn-
ogeographic associations or confounding effects. We did
not consider men and women separately but accounted
for the effect of gender through its use as a covariate.
Future studies investigating a sex difference might be use-
ful. Finally, both diets were hypocaloric. It is possible that
the genes shown to exert their effects through both diets,
actually do so through the commonality of caloric restric-
tion.
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